n-undec-5-ylamine | 33787-99-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: n-undec-5-ylamine
• 英文别名: undecan-5-amine；undecan-7-amine；5-undecylamine
• CAS: 33787-99-4
• 化学式: C₁₁H₂₅N
• 分子量: 171.326
• InChiKey: LEQCUCXZWOVKQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  12
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] THIAZOLE SULFONAMIDE AND OXAZOLE SULFONAMIDE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE THIAZOLE SULFONAMIDE ET OXAZOLE SULFONAMIDE KINASES
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2010104899A1

  公开（公告）日：2010-09-16

  The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents

  本发明提供了噻唑磺酰胺和恶唑磺酰胺化合物、含有该化合物的组合物，以及它们的制备方法和作为药物的使用方法。
• [EN] SUBSTITUTED SPIRO AZABICYCLICS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] DERIVES SPIRO AZABICYCLIQUES SUBSTITUES EN TANT QUE MODULATEURS DE L'ACTIVITE DU RECEPTEUR DE LA CHIMIOKINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005080376A1

  公开（公告）日：2005-09-01

  The present application describes modulators of CCR3 of formula (Ia) and (Ib): (I) or pharmaceutically acceptable salt forms thereof, wherein Z, R1, R2, R3, R4, R5, R5', R6, a, b, c, d, and u are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using said modulators are disclosed.

  本申请描述了公式(Ia)和(Ib)的CCR3调节剂：(I)或其药用可接受的盐形式，其中Z、R1、R2、R3、R4、R5、R5'、R6、a、b、c、d和u的定义如本文所述。此外，还公开了利用这些调节剂治疗和预防哮喘和过敏性疾病等炎症性疾病，以及类风湿关节炎和动脉粥样硬化等自身免疫病理的方法。
• FLUORIDE PROCESSING METHOD
  申请人：Jackson Alexander

  公开号：US20100285570A1

  公开（公告）日：2010-11-11

  The invention relates to methods for processing [ 18 F]-fluoride target water using a solid-support bound Cryptand of formula (I) and to apparatus for performing such methods. The resultant [ 18 F]-fluoride is useful for preparation of radiopharmaceuticals by nucleophilic fluorination, specifically for use in Positron Emission Tomography (PET).

  该发明涉及使用式(I)的固相支持结合的Cryptand处理[18F]-氟化物靶水的方法，以及用于执行此类方法的装置。所得的[18F]-氟化物可用于通过亲核氟化制备放射性药物，特别是用于正电子发射断层扫描（PET）中的使用。
• PREPARATION OF BIOCONJUGATES AND ANTIBODIES FOR THE IMMUNODETECTION OF ANATOXIN-A
  申请人：CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS

  公开号：US20190265233A1

  公开（公告）日：2019-08-29

  The present invention relates to bioconjugates and labeled derivatives of anatoxin-a, at different positions of the molecule, suitable for producing antibodies with high affinity and specificity for anatoxin-a. At the same time, the present invention also relates to the use of bioconjugates of anatoxin-a and labeled derivatives of anatoxin-a as assay antigens. Moreover, the present invention also relates to methods for analyzing, concentrating and extracting anatoxin-a using the antibodies obtained, sometimes together with assay antigens which are bioconjugates or labeled derivatives. This invention also provides a kit for analyzing anatoxin-a which comprises antibodies against this cyanotoxin sometimes together with assay antigens which are bioconjugates or labeled derivatives of anatoxin-a.

  本发明涉及生物共轭物和标记衍生物的解剖素以及不同分子位置的阿托西辛-a，适用于产生对阿托西辛-a具有高亲和力和特异性的抗体。同时，本发明还涉及使用阿托西辛-a的生物共轭物和标记衍生物作为测定抗原。此外，本发明还涉及利用所得抗体对阿托西辛-a进行分析、浓缩和提取的方法，有时还与生物共轭物或标记衍生物作为测定抗原一起使用。本发明还提供了一种用于分析阿托西辛-a的试剂盒，其中包括针对这种蓝藻毒素的抗体，有时还与生物共轭物或标记衍生物的测定抗原一起使用。
• Phenoxy Benzamide Compounds with Utility in the Treatment of Type 2 Diabetes and Obesity
  申请人：Johnstone Craig

  公开号：US20080280874A1

  公开（公告）日：2008-11-13

  Compounds of Formula (I): wherein: R 1 is methoxymethyl; R 2 is selected from —C(O)NR 4 R 5 , —SO 2 NR 4 R 5 , —S(O) p R 4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R 3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R 4 is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2; R 5 is hydrogen or (1-4C)alkyl; or R 4 and R 5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro-drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.

  化合物的式子为（I）： 其中：R1为甲氧甲基；R2选自—C（O）NR4R5，—SO2NR4R5，—S（O）pR4和HET-2；HET-1是一个5-或6-成员的，可选择性取代的C-连接杂环芳基环；HET-2是一个4-，5-或6-成员的，C-或N-连接可选择性取代的杂环烷基环；R3选自卤素，氟甲基，二氟甲基，三氟甲基，甲基，甲氧基和氰基；R4选自例如氢，可选择性取代的（1-4C）烷基和HET-2；R5为氢或（1-4C）烷基；或R4和R5与它们连接的氮原子一起可以形成由HET-3定义的杂环烷基环系统；HET-3例如为可选择性取代的N-连接的，4,5或6成员的，饱和或部分不饱和的杂环烷基环；p是（每次独立地）0，1或2；m为0或1；n为0，1或2；前提是当m为0时，n为1或2；或其盐，前药或溶剂。还描述了它们作为GLK激活剂的用途，含有它们的制药组合物以及它们的制备方法。